(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. Most Read from BloombergShares of the Alameda, California-based biotech firm opened at $25 each in New York, versus an IPO price of $15. The company sold 8.58 million shares on Thursday, after marketing 7.15 million shares for $13 to $15 apiece. The trading gives Scribe a market value of about $440.3 million, based on the outstanding shares listed in its filings. Affiliates of Sanofi SA had agreed to purchase about $7.5 million in shares at the IPO price as part of a concurrent private placement, the filings showed.